Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PROCTER & GAMBLE HEALTH vs MYLAN (US) - Comparison Results

MYLAN (US)
   Change

Mylan is one of the world’s leading generics and specialty pharmaceutical company. Its products span to customers in about 140 countries across the world. The company maintains one of the industry’s broadest and highest quality product portfolios, wh... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 PROCTER & GAMBLE HEALTH   MYLAN
EQUITY SHARE DATA
    PROCTER & GAMBLE HEALTH
Jun-23
MYLAN
Dec-18
PROCTER & GAMBLE HEALTH/
MYLAN
5-Yr Chart
Click to enlarge
High Rs5,3663,945-   
Low Rs3,8832,171-   
Sales per share (Unadj.) Rs740.71,815.3-  
Earnings per share (Unadj.) Rs138.249.3-  
Cash flow per share (Unadj.) Rs155.2389.2-  
Dividends per share (Unadj.) Rs95.000-  
Avg Dividend yield %2.10-  
Book value per share (Unadj.) Rs447.61,963.8-  
Shares outstanding (eoy) m16.60514.50-   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x6.21.7 370.5%   
Avg P/E ratio x33.562.0 53.9%  
P/CF ratio (eoy) x29.87.9 379.3%  
Price / Book Value ratio x10.31.6 663.4%  
Dividend payout %68.70-   
Avg Mkt Cap Rs m76,7611,573,481 4.9%   
No. of employees `000NA35.0 0.0%   
Total wages/salary Rs m2,0620-   
Avg. sales/employee Rs Th026,685.0-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th0724.6-  
INCOME DATA
Net Sales Rs m12,296933,975 1.3%  
Other income Rs m1840-   
Total revenues Rs m12,480933,975 1.3%   
Gross profit Rs m3,247241,678 1.3%  
Depreciation Rs m281174,877 0.2%   
Interest Rs m844,921 0.0%   
Profit before tax Rs m3,14221,880 14.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m847-3,481 -24.3%   
Profit after tax Rs m2,29525,361 9.0%  
Gross profit margin %26.425.9 102.0%  
Effective tax rate %27.0-15.9 -169.5%   
Net profit margin %18.72.7 687.3%  
BALANCE SHEET DATA
Current assets Rs m11,713521,531 2.2%   
Current liabilities Rs m6,791380,253 1.8%   
Net working cap to sales %40.015.1 264.6%  
Current ratio x1.71.4 125.8%  
Inventory Days Days26384 314.4%  
Debtors Days Days34393 368.1%  
Net fixed assets Rs m10,617181,176 5.9%   
Share capital Rs m166497 33.4%   
"Free" reserves Rs m7,2650-   
Net worth Rs m7,4311,010,390 0.7%   
Long term debt Rs m01,090,535 0.0%   
Total assets Rs m22,3302,710,259 0.8%  
Interest coverage x409.11.5 27,507.0%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.60.3 159.8%   
Return on assets %10.32.6 397.6%  
Return on equity %30.92.5 1,230.3%  
Return on capital %42.43.2 1,333.1%  
Exports to sales %00-   
Imports to sales %13.10-   
Net fx Rs m-1400-   
CASH FLOW
From Operations Rs m2,360194,080 1.2%  
From Investments Rs m-215-100,318 0.2%  
From Financial Activity Rs m-985-90,414 1.1%  
Net Cashflow Rs m1,1601,608 72.2%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for MYLAN (US) is United States Dollars. All data has been converted at 82.88 Rs / USD

Compare PROCTER & GAMBLE HEALTH With: ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Compare PROCTER & GAMBLE HEALTH With: UNICHEM LAB  SHUKRA PHARMA  LYKA LABS  SANDU PHARMA  AARTI DRUGS  



Today's Market

Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3% Sensex Today Trades Lower | Metal & PSB Stocks Shine | TCS, Apollo Tyre Drop 3%(10:30 am)

Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.